Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 10/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | CCR9 | P51686 | 1/20 | 0.30 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.30 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405964 | 0.81 | EPHB3 (0.39) | EPHB3IRAK4 | |
| SCHEMBL404837 | 0.78 | EPHB3 (0.39) | EPHB3RIPK2LCKIRAK4 | |
| SCHEMBL31030385 | 0.69 | EIF4A3 (0.47) | EPHB3RIPK2LCKNPC1RAB9A | |
| SCHEMBL29577063 | 0.66 | NNMT (0.42) | SMN1; SMN2NAPRTSIRT6 | |
| SCHEMBL16333365 | 0.66 | NNMT (0.42) | SMN1; SMN2NAPRTSIRT6 | |
| SCHEMBL1044120 | 0.66 | EPHB3 (0.58) | EPHB3RIPK2LCKDRD4DRD3 | |
| SCHEMBL27292456 | 0.64 | NAPRT (0.38) | EPHB3RIPK2LCKNPC1RAB9A | |
| SCHEMBL17796149 | 0.63 | SIRT6 (0.39) | NAPRTSIRT6 | |
| SCHEMBL15547132 | 0.63 | GABRP (0.44) | RAB9ASMN1; SMN2NAPRTSIRT6 | |
| SCHEMBL28824877 | 0.63 | KDM4E (0.46) | NPC1RAB9ANAPRTSIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022043-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | EPHB3 2273/4885RIPK2 553/4885LCK 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.